Skip to main content

Advertisement

SpringerLink
Log in

A retrospective study of patients with adult-onset Still’s disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need?

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The aims of this study were to look for clinical or serological markers able to predict the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) in patients with adult-onset Still’s disease (AOSD) and to evaluate the efficacy and safety of bDMARDs in AOSD. In a single-center retrospective study, 39 patients with AOSD were divided into two groups according to whether they were ever treated with bDMARDs or not. Literature was searched for articles dealing with possible predictors of the use of bDMARDs in AOSD. Among the 18 AOSD patients who received at least one bDMARD, the prevalence of pericarditis was higher than that in the other patients [p = 0.014, odds ratio (OR) = 13.4, 95 % confidence interval (CI) = 1.45 to 122]. Literature search retrieved another paper dealing with predictors of bDMARDs need in AOSD: the analysis pooling data from our series and this previous report confirmed pericarditis at disease onset as a predictor of bDMARDs need (p = 0.028, OR = 3.62, 95 % CI = 1.22 to 10.7). A complete remission was observed in 17 out of 18 patients treated with bDMARDs, allowing withdrawal or tapering of corticosteroid therapy (p < 0.001), but because of inefficacy or adverse events, some patients received more than one bDMARD during the course of the disease and 31 different trials of bDMARDs were needed. Pericarditis at disease onset may be a predictor of bDMARDs need in AOSD. These drugs have a good efficacy and safety profile and should be considered for patients not responding to conventional therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Efthimiou P, Paik PK, Bielory L (2006) Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis 65:564–572

    Article  CAS  PubMed  Google Scholar 

  2. Fautrel B (2008) Adult-onset Still disease. Best Pract Res Clin Rheumatol 22:773–792

    Article  PubMed  Google Scholar 

  3. Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621–668

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Rossi-Semerano L, Koné-Paut I (2012) Is Still’s disease an autoinflammatory syndrome? Int J Inflam 2012:480373

    PubMed  PubMed Central  Google Scholar 

  5. Rigante D, Cantarini L (2014) The systemic-onset variant of juvenile idiopathic arthritis needs to be recorded as an autoinflammatory syndrome: comment on the review by Nigrovic. Arthritis Rheumatol 66:2645

    Article  PubMed  Google Scholar 

  6. Maria AT, Le Quellec A, Jorgensen C, Touitou I, Rivière S, Guilpain P (2014) Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 13:1149–1159

    Article  CAS  PubMed  Google Scholar 

  7. Cavalli G, Franchini S, Aiello P et al (2015) Efficacy and safety of biological agents in adult-onset Still’s disease. Scand J Rheumatol 44:309–314

    Article  CAS  PubMed  Google Scholar 

  8. Kadavath S, Efthimiou P (2015) Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med 47:6–14

    Article  CAS  PubMed  Google Scholar 

  9. Yamaguchi M, Ohta A, Tsunematsu T et al (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19:424–430

    CAS  PubMed  Google Scholar 

  10. Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N (2010) Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol 37:2369–2376

    Article  CAS  PubMed  Google Scholar 

  11. Quartuccio L, Salvin S, Zuliani F, Mansutti E, De Vita S (2012) Pleuritis is a red flag for adult-onset Still’s disease which may require biologic therapies. Clin Exp Rheumatol 30:807

    PubMed  Google Scholar 

  12. Henter JI, Horne A, Aricó M et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131

    Article  PubMed  Google Scholar 

  13. Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG (2010) Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum 62:2530–2535

    Article  CAS  PubMed  Google Scholar 

  14. Ortiz-Sanjuán F, Blanco R, Calvo-Rio V et al (2014) Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still’s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 66:1659–1665

    Article  PubMed  Google Scholar 

  15. Nordström D, Knight A, Luukkainen R et al (2012) Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol 39:2008–2011

    Article  PubMed  Google Scholar 

  16. Colafrancesco S, Priori R, Valesini G (2015) Presentation and diagnosis of adult-onset Still’s disease: the implications of current and emerging markers in overcoming the diagnostic challenge. Expert Rev Clin Immunol 11:749–761

    Article  CAS  PubMed  Google Scholar 

  17. Parvez N, Carpenter JL (2009) Cardiac tamponade in Still disease: a review of the literature. South Med J 102:832–837

    Article  PubMed  Google Scholar 

  18. Cantarini L, Lopalco G, Selmi C et al (2015) Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. Autoimmun Rev 14:90–97

    Article  CAS  PubMed  Google Scholar 

  19. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA (2005) Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum 52:1794–1803

    Article  CAS  PubMed  Google Scholar 

  20. Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN (2007) Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 66:842–843

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L et al (2015) Efficacy of anakinra in refractory adult-onset Still’s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore) 94(39):e1554

    Article  Google Scholar 

  22. Giampietro C, Ridene M, Lequerre T et al (2013) Anakinra in adult-onset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken) 65:822–826

    Article  CAS  Google Scholar 

  23. Hong D, Yang Z, Han S et al (2014) Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. Drug Des Devel Ther 8:2345–2357

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Puechal X, deBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O et al (2011) Tocilizumab in refractory adult Still’s disease. Arthritis Care Res (Hoboken) 63:155–159

    Article  CAS  Google Scholar 

  25. De Boysson H, Fevrier J, Nicolle A, Auzary C, Geffray L (2013) Tocilizumab in the treatment of the adult-onset Still’s disease: current clinical evidence. Clin Rheumatol 32:141–147

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

None.

Author information

Authors and Affiliations

  1. Rheumatology and Clinical Immunology Unit, Spedali Civili of Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy

    Francesca Dall’Ara, Micol Frassi, Angela Tincani & Paolo Airò

  2. University of Pavia, Pavia, Italy

    Francesca Dall’Ara

  3. Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

    Francesca Dall’Ara & Angela Tincani

Authors
  1. Francesca Dall’Ara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Micol Frassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angela Tincani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paolo Airò
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesca Dall’Ara.

Ethics declarations

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dall’Ara, F., Frassi, M., Tincani, A. et al. A retrospective study of patients with adult-onset Still’s disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need?. Clin Rheumatol 35, 2117–2123 (2016). https://doi.org/10.1007/s10067-015-3164-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-015-3164-y

Keywords

Search

Navigation